PBC Ireland

Rogalska M, et al. 2026. Lipidome remodeling in primary biliary cholangitis. Lipids Health Dis (Feb 2026)

Su L, et al. 2025. Use of Ursodeoxycholic Acid and Cancer Risk for Patients With Primary Biliary Cholangitis. JAMA Netw Open (Dec 2025)

Choi J, et al. 2026. Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study. Hepatology (Feb 2026)

Buchanan-Peart KA, et al. 2025. Primary Biliary Cholangitis: Novel and Emerging Therapies. Gastroenterol Hepatol (N Y) (Nov 2025)

Lichtenstein GR. 2025. Exploring Current and Emerging Therapies for Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y) (Nov 2025)

Saeed M, et al. 2025. Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review. Front Med (Lausanne) (2025)

Yoon P, et al. 2026. Alkaline Phosphatase Normalization Occurs Less Frequently in Hispanic Patients with Primary Biliary Cholangitis. Clin Gastroenterol Hepatol (Jan 2026)

Zhou X, et al. 2026. IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury. Liver Int (Mar 2026)

Eruzun H, Gronbaek H. 2026. Awareness of Primary Biliary Cholangitis Among Turkish Physicians: A Cross-Sectional, Multicenter, Web-Based Survey. J Clin Med (Jan 2026)

Yang M, et al. 2025. Identification of Differentially Expressed Genes and Molecular Pathways Involved in Primary Biliary Cholangitis Using RNA-Seq. Genes (Basel) (Dec 2025)

Sukubo NG, et al. 2026. Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis. Gut (Jan 2026)

Scarlata GGM, Abenavoli L. 2026. The role of gut microbiota in the pathogenesis of primary biliary cholangitis: an immunological perspective. Expert Rev Clin Immunol (Jan 2026)

French J, et al. 2026. Higher sun exposure is associated with a reduced risk of primary biliary cholangitis. Int J Epidemiol (Jan 2026)

Xu J, et al. 2026. ATF3 Mediates the Immunoregulatory Role of the Tim-3 Pathway in Primary Biliary Cholangitis. J Gastroenterol Hepatol (Jan 2026)

Shen L, et al. 2026. Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis. J Gastroenterol (Jan 2026)

Han Z, et al. 2026. FCRL3 as a potential link between Benzo[a]pyrene exposure and primary biliary cholangitis: insights from comparative toxicogenomics and multi-omics analysis. BMC Gastroenterol (Jan 2026)

Williams EE, et al. 2026. Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study. Dig Dis Sci (Jan 2026)

Rahming N, et al. 2025. Dysgeusia-Driven Nutritional Decline in Cirrhosis: A Case of Autoimmune Hepatitis and Primary Biliary Cholangitis. Cureus (Dec 2025)

Baguley E, et al. 2026. Evaluating the clinical care, quality of life and overall experiences of patients with primary biliary cholangitis (PBC) during the pandemic: A Canadian mixed-methods study. PLoS One (2026)

Liu Y, et al. 2026. [A case of recurrent hypoglycemic coma episodes associated with primary biliary cholangitis and literature review]. Zhonghua Nei Ke Za Zhi (Jan 2026)

Wang M, et al. 2025. Genetic evidence supports primary biliary cholangitis as a risk factor for lacunar stroke. iScience (Dec 2025)

Zhou Y, et al. 2026. Variation in microbiome and metabolites is associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus. Microbiol Spectr (Feb 2026)

Arvaniti P, et al. 2025. Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis. J Transl Autoimmun (Dec 2025)

Kim GE, et al. 2025. Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report. Case Reports Hepatol (2025)

Zang B, et al. 2025. Decoding the Gut Microbiome in Primary Sjögren's Syndrome and Primary Biliary Cholangitis: Shared Dysbiosis, Distinct Patterns, and Associations with Clinical Features. Microorganisms (Nov 2025)

Romeo M, et al. 2025. The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives. J Pers Med (Dec 2025)

Wang Z, et al. 2025. Vitamin D attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization. Sci Rep (Dec 2025)

Chen Z, et al. 2025. The causal relationship between inflammatory bowel disease and primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study. Medicine (Baltimore) (Dec 2025)

Li Y, et al. 2025. Systemic inflammatory response index: a novel predictor for cardiovascular disease risk in patients with primary biliary cholangitis. Eur J Med Res (Dec 2025)

Wang W, et al. 2025. Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia. Front Immunol (2025)

Böttcher MH, et al. 2026. Association between quality of life and inflammation and fibrosis markers in primary biliary cholangitis over three-year follow-up. Scand J Gastroenterol (Jan 2026)

Invernizzi P, et al. 2026. Primary biliary cholangitis (PBC): evolving approaches and expert perspectives. Expert Rev Gastroenterol Hepatol (Jan 2026)

Yang P, et al. 2025. Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report. Front Med (Lausanne) (2025)

Jin M. 2025. Comment on "Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Dec 2025)

Chen PT, Chen HW. 2025. Reply to "Comment on 'Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan'". J Formos Med Assoc (Dec 2025)

Dar MS, et al. 2025. Randomized Controlled Trial Evidence on Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Int J Hepatol (2025)

Mimura S, et al. 2025. Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets. J Clin Med (Nov 2025)

Mandea M, et al. 2025. From Isolation to Information: Launching an Online Community for Patients with Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and Autoimmune Hepatitis in Romania-A Descriptive Study. Healthcare (Basel) (Dec 2025)

Luo PY, et al. 2025. Autophagy of Kupffer cells modulates CD8 T cell activation in primary biliary cholangitis. Gut (Dec 2025)

Stein K, et al. 2025. Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapy. Z Gastroenterol (Dec 2025)

Gish RG, et al. 2025. Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States. J Med Econ (Dec 2025)

van Hooff MC, et al. 2025. Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study. Am J Gastroenterol (Dec 2025)

Han J, Xu Q. 2025. Diagnostic Pitfalls in Primary Biliary Cholangitis: Delta Bilirubin and Lipoprotein-X Interferences. Clin Lab (Dec 2025)

Jin Y, et al. 2025. Quantitative detection of anti-centromere antibodies in primary biliary cholangitis: value of chemiluminescence immunoassay. Scand J Clin Lab Invest (2025)

Koriem KMM. 2025. Tumor necrosis factor alpha-induced protein 3: Biomarker discovery and therapeutic advancement in primary biliary cholangitis. World J Hepatol (Nov 2025)

Liu Z, et al. 2026. Bile Acid Metabolites Control Th17/Treg Balance in Primary Biliary Cholangitis: Mechanisms of Disease Progression and Therapeutic Targets. J Gastroenterol Hepatol (Jan 2026)

Kumar S, et al. 2025. Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States. Adv Ther (Dec 2025)

Vierling JM, et al. 2025. Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial. Hepatol Commun (Dec 2025)

Haque T, et al. 2025. AMA-Negative Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome Presenting With Bullous Pemphigoid: A Case Report. Clin Case Rep (Dec 2025)

Rogalska M, et al. 2025. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep (Nov 2025)

Mandea M, et al. 2025. Profile of Patients with Primary Biliary Cholangitis and Evaluation of Response to Ursodeoxycholic Acid in a Romanian Center-Retrospective Study. J Clin Med (Nov 2025)

Ma X, et al. 2025. Proteomics identifies complement protein signatures in patients with primary biliary cholangitis. Eur J Med Res (Nov 2025)

Choi G, et al. 2025. Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision. Dig Dis Sci (Nov 2025)

Chen JL, et al. 2025. Real-world performance of transient elastography in assessing advanced fibrosis in Chinese patients with primary biliary cholangitis. World J Gastroenterol (Nov 2025)

Angelara M, et al. 2025. Primary biliary cholangitis. Treatment options in 2025. A narrative review. Front Immunol (2025)

Bersuch LA, De Gottardi A. 2025. Exploring Maralixibat for Treatment-Resistant Pruritus in Intrahepatic Cholestasis of Pregnancy and Primary Biliary Cholangitis: A Case Report. Am J Case Rep (Nov 2025)

Ritter TE, et al. 2025. Association of liver biomarker values beyond current thresholds and negative clinical outcomes in primary biliary cholangitis: analysis of a real-world healthcare claims database. J Comp Eff Res (Dec 2025)

Lantinga MA. 2025. What the European Reference Network Registry for Rare Liver Diseases Tells Us About Primary Biliary Cholangitis in European Practice. United European Gastroenterol J (Dec 2025)

Zhang Y, et al. 2025. HSC-derived exosomal miR-122-5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis. Front Immunol (2025)

Bantel H, et al. 2025. Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations. Hepatol Commun (Dec 2025)

Popescu I. 2025. PPARevolution. First PPARδ Agonist and a Dual PPARα/PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis. J Cell Mol Med (Nov 2025)

Pei Y, et al. 2025. Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis'. Aliment Pharmacol Ther (Nov 2025)

Tang X, You X. 2025. Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis. Gut Pathog (Nov 2025)

Tana MM, Hirschfield GM. 2026. Primary Biliary Cholangitis. JAMA (Jan 2026)

Lakshmanan V, Morris L. 2025. Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis. Cureus (Oct 2025)

Zhou AE, et al. 2025. Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib. J Drugs Dermatol (Nov 2025)

Liu C, et al. 2026. Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis-The Role of Biochemical Response as a Dynamic Predictor. Aliment Pharmacol Ther (Feb 2026)

Hirschfield GM, et al. 2026. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol (Jan 2026)

Lohse AW, Assis DN. 2026. Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis. Lancet Gastroenterol Hepatol (Jan 2026)

Kowdley KV, et al. 2026. Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Feb 2026)

Kuo SZ, et al. 2025. Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Oct 2025)

Jamal F, et al. 2025. Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines (Sep 2025)

Ye X, et al. 2025. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis. Ann Hepatol (Oct 2025)

Zhang M, et al. 2025. The Genomics/Genetics of Primary Biliary Cholangitis: The Case for a Functional SNP rs10893900 in ETS1/FLI1 and Review of the Literature. Clin Rev Allergy Immunol (Oct 2025)

Li J, et al. 2026. Autophagy Sustained the Activation and Survival of Liver-infiltrating CD8 T Cells in Primary Biliary Cholangitis. Immunol Invest (Jan 2026)

Tao Y, et al. 2025. The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data. Front Immunol (2025)

Ren W, et al. 2025. Identification of galangin as a therapeutic candidate for primary biliary cholangitis via systematic druggable genome-wide Mendelian randomization analysis and experimental validation. Front Pharmacol (2025)

Passos PRC, et al. 2025. Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors. Am J Transplant (Oct 2025)

Harada K, et al. 2025. Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid. Hum Pathol (Dec 2025)

Gordon SC, et al. 2025. Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis. BMJ Open Gastroenterol (Oct 2025)

Gerussi A, et al. 2025. Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER). United European Gastroenterol J (Dec 2025)

Forero Vásquez BN, et al. 2025. Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report. Cureus (Sep 2025)

Curto A, et al. 2025. Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies. World J Clin Cases (Oct 2025)

Chen R, et al. 2025. Innate immunity of bile and cholangiocytes in primary biliary cholangitis. Front Immunol (2025)

Das TS, Vuppalanchi R. 2025. Recent Advances in Primary Biliary Cholangitis Treatment. Clin Liver Dis (Nov 2025)

Shen G, et al. 2026. The effects of lifestyle factors on primary biliary cholangitis ascertained by two-sample Mendelian randomization. Am J Med Sci (Jan 2026)

Yu C, et al. 2025. Impact of the prognostic nutritional index on the recompensation of patients with decompensated primary biliary cholangitis. Front Immunol (2025)

. 2025. Correction to 'Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study'. Liver Int (Nov 2025)

Ye K, et al. 2025. Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy. Front Immunol (2025)

Herta T, et al. 2025. Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care. Ann Hepatol (Oct 2025)

Koc OM, et al. 2026. Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases. Lancet Gastroenterol Hepatol (Jan 2026)

Floreani A, et al. 2025. An update on novel investigational agents for the treatment of primary biliary cholangitis. Expert Opin Investig Drugs (Oct 2025)

Zhang J, Hirata Y. 2026. Response to "Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others?". Hepatol Res (Feb 2026)

Corpechot C, et al. 2025. Bezafibrate for primary biliary cholangitis: time to act on the evidence. Nat Rev Gastroenterol Hepatol (Dec 2025)

Arase Y, et al. 2025. Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial. Hepatol Commun (Nov 2025)

Luo H, et al. 2025. Causal association between dietary factors and Primary Biliary Cholangitis: A Mendelian randomization study. Medicine (Baltimore) (Oct 2025)

Martins A, et al. 2025. Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis. Hepatology (Jul 2025)

Wong YJ, et al. 2026. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. J Hepatol (Feb 2026)

Ma H, et al. 2026. Profiling of circulating T follicular helper and T peripheral helper cell subsets in patients with primary biliary cholangitis. Immunol Lett (Feb 2026)

Zhang X, et al. 2025. The Depletion of Plasma Cells but Not CD20B Cells Alleviates Primary Biliary Cholangitis. Liver Int (Nov 2025)

(Facebook is for Irish PBC patients only)

Recent News

URSO Calculator

Feb 4th, 2026
New publication alert in TAIRD!

Jan 1st, 2026
PBC Ireland commences collaboration with C-PATH

Jan 17th, 2026
PBC Ireland to present at Irish Liver Foundation @ Royal College of Surgeons, Ire.

Jan 15th, 2026
PBC Ireland launches their Patient Clinic Visit Questionnaire.

Jul 27th, 2025
The PBC Ireland Patient Registry is now LIVE!

Jul 26th, 2025
PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC

May 8th, 2025
PBC Ireland Launched!

Publications(100 publications from PubMed)

Recent News

Publications
(100 publications from PubMed)